| Title |
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing
|
|---|---|
| Published in |
Clinical Pharmacology & Therapeutics, May 2013
|
| DOI | 10.1038/clpt.2013.103 |
| Pubmed ID | |
| Authors |
S G Leckband, J R Kelsoe, H M Dunnenberger, A L George, E Tran, R Berger, D J Müller, M Whirl‐Carrillo, K E Caudle, M Pirmohamed |
| Abstract |
Human leukocyte antigen B (HLA-B) is a gene that encodes a cell surface protein involved in presenting antigens to the immune system. The variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in response to carbamazepine treatment. We summarize evidence from the published literature supporting this association and provide recommendations for the use of carbamazepine based on HLA-B genotype (also available on PharmGKB: http://www.pharmgkb.org). The purpose of this article is to provide information to allow the interpretation of clinical HLA-B*15:02 genotype tests so that the results can be used to guide the use of carbamazepine. The guideline provides recommendations for the use of carbamazepine when HLA-B*15:02 genotype results are available. Detailed guidelines regarding the selection of alternative therapies, the use of phenotypic tests, when to conduct genotype testing, and cost-effectiveness analyses are beyond the scope of this document. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are published and updated periodically on the PharmGKB website at (http://www.pharmgkb.org). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 171 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Hungary | 1 | <1% |
| Netherlands | 1 | <1% |
| Brazil | 1 | <1% |
| Sweden | 1 | <1% |
| United Kingdom | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 164 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 26 | 15% |
| Student > Master | 24 | 14% |
| Researcher | 21 | 12% |
| Student > Ph. D. Student | 20 | 12% |
| Other | 14 | 8% |
| Other | 41 | 24% |
| Unknown | 25 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 50 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 30 | 18% |
| Biochemistry, Genetics and Molecular Biology | 21 | 12% |
| Agricultural and Biological Sciences | 14 | 8% |
| Unspecified | 5 | 3% |
| Other | 21 | 12% |
| Unknown | 30 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2024.
All research outputs
#5,393,063
of 25,837,817 outputs
Outputs from Clinical Pharmacology & Therapeutics
#1,106
of 4,619 outputs
Outputs of similar age
#43,356
of 210,636 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#10
of 30 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,619 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,636 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.